The DPP4 inhibitor, vildagliptin prevented tumor progression by suppressing the proangiogenic role of CCL2 (Figure 2A) but did not affect VEGF, VEGF receptor 2 or angiopoietin-1 levels. The gene discussed is DPP4; the disease is neoplasm.